241 related articles for article (PubMed ID: 26101460)
21. Novel benzenediamine derivative FC99 ameliorates zymosan-induced arthritis by inhibiting RORγt expression and Th17 cell differentiation.
Ji J; Dou H; Li X; Song Y; Li X; Li E; Tan R; Hou Y
Acta Biochim Biophys Sin (Shanghai); 2014 Oct; 46(10):829-36. PubMed ID: 25187413
[TBL] [Abstract][Full Text] [Related]
22. Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect.
Jimeno R; Leceta J; Garín M; Ortiz AM; Mellado M; Rodríguez-Frade JM; Martínez C; Pérez-García S; Gomariz RP; Juarranz Y
J Leukoc Biol; 2015 Aug; 98(2):257-69. PubMed ID: 25957307
[TBL] [Abstract][Full Text] [Related]
23. Optimal clearance of Sporothrix schenckii requires an intact Th17 response in a mouse model of systemic infection.
Ferreira LS; Gonçalves AC; Portuondo DL; Maia DC; Placeres MC; Batista-Duharte A; Carlos IZ
Immunobiology; 2015 Aug; 220(8):985-92. PubMed ID: 25776919
[TBL] [Abstract][Full Text] [Related]
24. Antrodia cinnamomea Extract Inhibits Th17 Cell Differentiation and Ameliorates Imiquimod-Induced Psoriasiform Skin Inflammation.
Li MH; Wu HC; Yao HJ; Lin CC; Wen SF; Pan IH
Am J Chin Med; 2015; 43(7):1401-17. PubMed ID: 26477794
[TBL] [Abstract][Full Text] [Related]
25. Expression of Th17-related genes in PHA/IL-2-activated human T cells by Fas signaling via caspase-1- and Stat3-dependent pathway.
Su CC; Lin HC; Lin YP; Shan YS; Yang BC
Cell Immunol; 2013 Feb; 281(2):101-10. PubMed ID: 23590971
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis.
Mus AM; Cornelissen F; Asmawidjaja PS; van Hamburg JP; Boon L; Hendriks RW; Lubberts E
Arthritis Rheum; 2010 Apr; 62(4):1043-50. PubMed ID: 20131264
[TBL] [Abstract][Full Text] [Related]
27. Green tea EGCG, T cells, and T cell-mediated autoimmune diseases.
Wu D; Wang J; Pae M; Meydani SN
Mol Aspects Med; 2012 Feb; 33(1):107-18. PubMed ID: 22020144
[TBL] [Abstract][Full Text] [Related]
28. Mycobacterium tuberculosis RpfE promotes simultaneous Th1- and Th17-type T-cell immunity via TLR4-dependent maturation of dendritic cells.
Choi HG; Kim WS; Back YW; Kim H; Kwon KW; Kim JS; Shin SJ; Kim HJ
Eur J Immunol; 2015 Jul; 45(7):1957-71. PubMed ID: 25907170
[TBL] [Abstract][Full Text] [Related]
29. Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease.
Perreau M; Rozot V; Welles HC; Belluti-Enders F; Vigano S; Maillard M; Dorta G; Mazza-Stalder J; Bart PA; Roger T; Calandra T; Nicod L; Harari A
Eur J Immunol; 2013 Apr; 43(4):939-48. PubMed ID: 23436562
[TBL] [Abstract][Full Text] [Related]
30. Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen.
Fukui M; Shinjo K; Umemura M; Shigeno S; Harakuni T; Arakawa T; Matsuzaki G
Microbiol Immunol; 2015 Dec; 59(12):735-43. PubMed ID: 26577130
[TBL] [Abstract][Full Text] [Related]
31. Th17 cells in autoimmune diseases.
Han L; Yang J; Wang X; Li D; Lv L; Li B
Front Med; 2015 Mar; 9(1):10-9. PubMed ID: 25652649
[TBL] [Abstract][Full Text] [Related]
32. Predominance of Th17 over regulatory T-cells in pleural effusions of patients with lung cancer implicates a proinflammatory profile.
Prado-Garcia H; Romero-Garcia S; Rumbo-Nava U; Lopez-Gonzalez JS
Anticancer Res; 2015 Mar; 35(3):1529-35. PubMed ID: 25750307
[TBL] [Abstract][Full Text] [Related]
33. The deviated balance between regulatory T cell and Th17 in autoimmunity.
Jadidi-Niaragh F; Mirshafiey A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):727-39. PubMed ID: 22316060
[TBL] [Abstract][Full Text] [Related]
34. Inorganic arsenic represses interleukin-17A expression in human activated Th17 lymphocytes.
Morzadec C; Macoch M; Robineau M; Sparfel L; Fardel O; Vernhet L
Toxicol Appl Pharmacol; 2012 Aug; 262(3):217-22. PubMed ID: 22617429
[TBL] [Abstract][Full Text] [Related]
35. Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases.
Yamagata T; Skepner J; Yang J
Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):405-14. PubMed ID: 26358867
[TBL] [Abstract][Full Text] [Related]
36. Are Th17 cells and their cytokines a therapeutic target in Guillain-Barré syndrome?
Wu X; Wang J; Liu K; Zhu J; Zhang HL
Expert Opin Ther Targets; 2016; 20(2):209-22. PubMed ID: 26357850
[TBL] [Abstract][Full Text] [Related]
37. Identity crisis of Th17 cells: many forms, many functions, many questions.
Sundrud MS; Trivigno C
Semin Immunol; 2013 Nov; 25(4):263-72. PubMed ID: 24239567
[TBL] [Abstract][Full Text] [Related]
38. Protection against Streptococcus pneumoniae serotype 1 acute infection shows a signature of Th17- and IFN-γ-mediated immunity.
Marqués JM; Rial A; Muñoz N; Pellay FX; Van Maele L; Léger H; Camou T; Sirard JC; Benecke A; Chabalgoity JA
Immunobiology; 2012 Apr; 217(4):420-9. PubMed ID: 22204818
[TBL] [Abstract][Full Text] [Related]
39. Involvement of Th17 cells in patients of urothelial carcinoma of bladder.
Chugh S; Anand V; Swaroop L; Sharma M; Seth A; Sharma A
Hum Immunol; 2013 Oct; 74(10):1258-62. PubMed ID: 23827655
[TBL] [Abstract][Full Text] [Related]
40. TGF-β converts Th1 cells into Th17 cells through stimulation of Runx1 expression.
Liu HP; Cao AT; Feng T; Li Q; Zhang W; Yao S; Dann SM; Elson CO; Cong Y
Eur J Immunol; 2015 Apr; 45(4):1010-8. PubMed ID: 25605286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
